• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Falls 1%; Eli Lilly Raises Annual Guidance

    8/8/23 12:06:59 PM ET
    $BURU
    $DRUG
    $DTSS
    $LLY
    Industrial Machinery/Components
    Miscellaneous
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BURU alert in real time by email

    U.S. stocks were lower midway through trading, with the Dow Jones falling over 1% on Tuesday.

    The Dow traded down 1.05% to 35,099.88 while the NASDAQ fell 1.47% to 13,788.21. The S&P 500, also fell, dropping, 1.09% to 4,469.36.

    Check This Out: Top 5 Tech Stocks Which Could Rescue Your Portfolio This Month

     

    Leading and Lagging Sectors

    • Health care shares jumped by 0.5% on Tuesday.
    • In trading on Tuesday, financial shares fell 1.8%.

     

    Top Headline

    Eli Lilly and Company (NYSE:LLY) reported upbeat second-quarter results and raised its annual guidance.

    Eli Lilly reported sales of $$8.31 billion, up 28% Y/Y, beating the consensus of $7.58 billion. Eli Lilly posted an adjusted EPS of $2.11, beating the consensus of $1.99.

    The company also raised its annual revenue forecast to $33.4-$33.9 billion from prior guidance of $31.2-$31.7 billion versus the consensus of $31.44 billion. The company sees adjusted EPS Of $9.70-$9.90 from prior guidance of $8.65-$8.85 compared to the consensus of $8.71.

     

    Equities Trading UP

    • Nuburu, Inc. (NYSE:BURU) shares shot up 79% to $1.0387 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser technology.
    • Shares of Paymentus Holdings, Inc. (NYSE:PAY) got a boost, shooting 28% to $13.68 after the company reported better-than-expected second-quarter financial results.
    • Bright Minds Biosciences Inc. (NASDAQ:DRUG) shares were also up, gaining 42% to $4.58 after the company disclosed data for BMB-101.

     

    Equities Trading DOWN

    • Proterra Inc. (NASDAQ:PTRA) shares dropped 81% to $0.2768 after the company announced it filed for Chapter 11 bankruptcy.
    • Shares of SeaChange International, Inc. (NASDAQ:SEAC) were down 40% to $4.70 after the company announced voluntary SEC deregistration and Nasdaq delisting.
    • Datasea Inc. (NASDAQ:DTSS) was down, falling 40% to $0.6890. Datasea said on August 1 that it entered into two separate subscription agreements with a certain non-U.S. investor to sell an aggregate of 4.8 million shares of common stock at $1.20 per share.

    Also Check This Out: McKesson, Kinder Morgan And 2 Other Stocks Insiders Are Selling

     

    Commodities

    In commodity news, oil traded down 0.7% to $81.36 while gold traded down 0.4% at $1,961.40.

    Silver traded down 1.6% to $22.855 on Tuesday while copper fell 1.9% to $3.7615.

     

    Euro zone

    European shares were lower today. The eurozone’s STOXX 600 fell 0.31%, London’s FTSE 100 fell 0.47% while Spain’s IBEX 35 Index fell 0.8% The German DAX declined 1.19% French CAC 40 fell 0.78% and Italy’s FTSE MIB Index declined 2.15%.

    French trade deficit shrank to EUR 6.7 billion in June, recording the lowest level since Aug. 2021, while the country posted a current account surplus of EUR 0.8 billion in June compared to a EUR 0.7 billion deficit in the prior month. The annual inflation rate in Germany fell to 6.2% in July from 6.4% in June. Retail sales in the UK increased 1.8% year-over-year in July.

     

    Asia Pacific Markets

    Asian markets closed mostly lower on Tuesday, with Japan’s Nikkei 225 rising 0.38%, China’s Shanghai Composite Index falling 0.25% and Hong Kong’s Hang Seng Index declining 1.81%. India’s S&P BSE Sensex, meanwhile, fell 0.1%.

    The gauge for Japan's service sector sentiment rose to 54.4 in July from 53.6 in the earlier month, while average cash earnings in the country rose by 2.3% year-over-year in June. Japan's current account surplus widened to JPY 1,508.8 billion in June compared to JPY 497.9 billion in the year-ago month. Chinese trade surplus shrank to $80.6 billion in July from $102.7 billion in the year-ago period.

    Australia's NAB business confidence index rose to 2 in July versus a revised reading of -1 in the previous month, while the Westpac-Melbourne Institute Consumer Sentiment index declined by 0.4% month-over-month to a reading of 81.0 in August.

     

    Economics

    • The NFIB Small Business Optimism Index rose for a third straight month to a reading of 91.9 in July.
    • The U.S. trade deficit shrank to a three-month low level of $65.5 billion in June versus a revised $68.3 billion in May.
    • Exports from the U.S. fell by $0.3 billion to $247.5 billion in June, while imports fell by $3.1 billion to $313.0 billion.
    • Wholesale inventories in the U.S. fell 0.5% from a month ago in June versus the preliminary estimate of a 0.3% decline and compared to a revised 0.4% decline in the previous month.

    Now Read This: DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 107,566,780 cases with around 1,170,780 deaths. India confirmed a total of at least 44,996,030 cases and 531,910 deaths, while France reported over 40,138,560 COVID-19 cases with 167,640 deaths. In total, there were at least 692,993,500 cases of COVID-19 worldwide with more than 6,905,480 deaths.

    Get the next $BURU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BURU
    $DRUG
    $DTSS
    $LLY

    CompanyDatePrice TargetRatingAnalyst
    Eli Lilly and Company
    $LLY
    1/7/2026$1250.00Buy
    UBS
    Eli Lilly and Company
    $LLY
    12/16/2025$1230.00Neutral → Buy
    Daiwa Securities
    Eli Lilly and Company
    $LLY
    12/15/2025$951.00 → $1145.00Buy
    Goldman
    Eli Lilly and Company
    $LLY
    12/15/2025$1286.00 → $1268.00Buy
    BofA Securities
    Eli Lilly and Company
    $LLY
    11/13/2025$1165.00Sector Outperform
    Scotiabank
    Eli Lilly and Company
    $LLY
    11/10/2025$1104.00Market Perform → Outperform
    Leerink Partners
    Eli Lilly and Company
    $LLY
    10/20/2025$840.00 → $930.00Outperform
    BMO Capital Markets
    Eli Lilly and Company
    $LLY
    10/14/2025Hold → Buy
    Erste Group
    More analyst ratings

    $BURU
    $DRUG
    $DTSS
    $LLY
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Paymentus Holdings Inc.

    SCHEDULE 13G/A - Paymentus Holdings, Inc. (0001841156) (Subject)

    2/11/26 4:57:14 PM ET
    $PAY
    Real Estate

    SEC Form S-1 filed by Nuburu Inc.

    S-1 - Nuburu, Inc. (0001814215) (Filer)

    2/10/26 12:15:42 PM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.

    SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

    2/6/26 3:00:09 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BURU
    $DRUG
    $DTSS
    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BURU
    $DRUG
    $DTSS
    $LLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BURU
    $DRUG
    $DTSS
    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $BURU
    $DRUG
    $DTSS
    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    UBS resumed coverage on Eli Lilly with a new price target

    UBS resumed coverage of Eli Lilly with a rating of Buy and set a new price target of $1,250.00

    1/7/26 9:11:47 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Eli Lilly from Neutral to Buy and set a new price target of $1,230.00

    12/16/25 8:49:23 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman reiterated coverage on Eli Lilly with a new price target

    Goldman reiterated coverage of Eli Lilly with a rating of Buy and set a new price target of $1,145.00 from $951.00 previously

    12/15/25 10:37:03 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Finance, & CAO Zakrowski Donald A was granted 584 shares, increasing direct ownership by 21% to 3,423 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/11/26 4:27:28 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP&Pres, LLY USA&Global Capab Yuffa Ilya was granted 4,163 shares, increasing direct ownership by 15% to 32,304 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/11/26 4:26:05 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP,Pres LLY Oncology&HdCorpBD Van Naarden Jacob was granted 4,866 shares, increasing direct ownership by 22% to 26,626 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/11/26 4:25:13 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BURU
    $DRUG
    $DTSS
    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    NUBURU Establishes Strategic Equity Position in Heckler & Koch AG, Advancing Integrated Defense Platform Strategy

    Aligning Non-Kinetic Capabilities with Globally Deployed NATO Defense Systems NUBURU, Inc. (NYSE:BURU), a dual-use Defense & Security platform company focused on non-kinetic effects, directed-energy technologies, and software-orchestrated defense systems, today announced that it has established a strategic equity position in Heckler & Koch AG ("H&K"), one of the world's most recognized manufacturers of small arms and kinetic defense systems serving NATO and allied forces. The investment represents a deliberate step in NUBURU's strategy to position its non-kinetic technologies alongside globally deployed kinetic platforms within modern, multi-domain defense architectures. Strategic Ind

    2/11/26 7:35:00 AM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    NUBURU, Inc. Completes First Tranche of Preferred Equity Restructuring, Eliminating Approximately $8.4 Million of Series A Preferred Liabilities

    Preferred Equity Restructuring Eliminates Approximately 40% of Series A Preferred Liabilities Without Cash Redemption NUBURU, Inc. (NYSE:BURU), a developer of high-performance blue laser technology and an emerging defense and security technology platform, today announced the completion of the first tranche of a preferred equity restructuring transaction that materially simplifies its capital structure and reduces legacy balance-sheet overhang. The completed first tranche resulted in the restructuring and effective elimination of approximately $8.4 million of Series A Convertible Preferred Stock liabilities, representing approximately 844,938 shares of Series A Preferred Stock, and appro

    2/10/26 7:05:00 AM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    $BURU
    $DRUG
    $DTSS
    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Paymentus Holdings Inc.

    SC 13G - Paymentus Holdings, Inc. (0001841156) (Subject)

    12/10/24 5:08:45 PM ET
    $PAY
    Real Estate

    Amendment: SEC Form SC 13D/A filed by Nuburu Inc.

    SC 13D/A - Nuburu, Inc. (0001814215) (Subject)

    11/25/24 8:59:19 PM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    Amendment: SEC Form SC 13G/A filed by Paymentus Holdings Inc.

    SC 13G/A - Paymentus Holdings, Inc. (0001841156) (Subject)

    11/14/24 4:05:57 PM ET
    $PAY
    Real Estate

    $BURU
    $DRUG
    $DTSS
    $LLY
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

    INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer an

    11/6/25 4:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NUBURU Strengthens Balance Sheet, Advances Defense-Tech Acquisition Program and Revamps Blue-Laser Business

    Executing Transformation Plan spanning Maddox Defense drones, Tekne special-mission vehicles, and Orbit critical-infrastructure software to build a unified defense-tech platform with expanding NATO traction. Blue-laser technology' business acquisition on track. NUBURU, Inc. (NYSE:BURU) ("NUBURU" or the "Company") continued strengthening its balance sheet during the quarter through disciplined capital deployment, selective drawdowns under its Standby Equity Purchase Agreement when beneficial, and further reduction of legacy payables. Cash on hand remains robust as NUBURU strategically allocates capital to high-value defense and security growth initiatives under its Transformation Plan. "We

    11/6/25 7:30:00 AM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    $BURU
    $DRUG
    $DTSS
    $LLY
    Financials

    Live finance-specific insights

    View All

    Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

    Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound.Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU. Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from in

    2/4/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Paymentus to Report Fourth Quarter and Full Year 2025 Earnings Results and Host Webcast on February 23, 2026

    Paymentus Holdings, Inc. ("Paymentus") (NYSE:PAY), a leading provider of cloud-based bill payment technology solutions, will announce its fourth quarter and full year 2025 financial results after the market close on Monday, February 23, 2026. The Company will discuss the results in a live webcast at 5 p.m. Eastern Time on February 23, 2026. Event: Paymentus Fourth Quarter and Full Year 2025 Earnings Conference Call Date: Monday, February 23, 2026 Time: 5:00 p.m. Eastern Time Live Call: +1 833 470 1428 (U.S. Toll-Free) or +1 646 844 6383 (International) Access Code: 933764 Webcast: The 'Investor Relations

    2/3/26 4:05:00 PM ET
    $PAY
    Real Estate

    Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

    INDIANAPOLIS, Jan. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2025 financial results on February 4, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.   The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into h

    1/21/26 10:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care